Physician profile
Eric M Arnett
NPI 1205235363
$6,846.73
in general payments reported to CMS, 2019-2025
36 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.67 · 2022: $987 · 2023: $1,970 · 2024: $1,850 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,846.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,189.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $831.42 | 2023-2025 | |
| Abbvie INC. | $652.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $595.88 | 2022-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Lilly USA, LLC | $594.88 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $415.22 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $315.45 | 2022-2025 | Azstarys |
| Amgen INC. | $281.79 | 2022-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $224.59 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $168.95 | 2023-2024 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $167.86 | 2023-2025 | Veozah, Myrbetriq |
| Avanir Pharmaceuticals, INC. | $141.68 | 2022 | |
| Abbott Laboratories | $136.60 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.83 | 2022-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.37 | 2022-2025 | Xifaxan, Trulance |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Arnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.